| Title |
Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents
|
|---|---|
| Published in |
American Journal of Clinical Dermatology, February 2016
|
| DOI | 10.1007/s40257-016-0177-5 |
| Pubmed ID | |
| Authors |
Sumana Devata, Ryan A. Wilcox |
| Abstract |
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of extranodal lymphomas involving the skin. Diagnosis of the two main subtypes of CTCL-mycosis fungoides (MF) and Sézary syndrome (SS)-is based on the International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer (ISCL/EORTC) classification system, which utilizes clinical, histopathological, molecular biologic, and immunopathologic features. Risk stratification, based on TNMB (tumor, node, metastasis, and blood) staging, provides prognostic information, with limited-stage disease conferring the longest median overall survival. Skin-directed therapies are preferred in the management of limited-stage disease, whereas advanced-stage disease requires systemic therapies. As the mechanisms of CTCL pathogenesis are increasingly understood, new monoclonal antibodies, checkpoint inhibitors, immunomodulatory agents, and small molecules are under investigation and may provide additional therapeutic options for those with advanced CTCL. This review examines the current landscape of targeted therapies in the treatment of CTCLs. |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 64 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Other | 6 | 9% |
| Student > Ph. D. Student | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Student > Bachelor | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 20 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 30% |
| Biochemistry, Genetics and Molecular Biology | 10 | 16% |
| Immunology and Microbiology | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Chemistry | 3 | 5% |
| Other | 5 | 8% |
| Unknown | 20 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2023.
All research outputs
#7,475,276
of 23,495,502 outputs
Outputs from American Journal of Clinical Dermatology
#496
of 1,001 outputs
Outputs of similar age
#102,259
of 299,113 outputs
Outputs of similar age from American Journal of Clinical Dermatology
#9
of 15 outputs
Altmetric has tracked 23,495,502 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,001 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,113 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.